CIK 0001706431 · Large accelerated filer
Vir Biotechnology, Inc.
Sign in to watch- Ticker
- VIR
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 812730369
- Phone
- 415-906-4324
- Business address
- 1800 OWENS STREET, SUITE 900, SAN FRANCISCO, CA, 94158
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $41,939
- in 1 filing, $42K under 10b5-1 plans
Net −$41,939. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 46 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-02-16 | Virgin Herbert EVP, Research & CSO | Grant or award | +30,000 | 63,200 | ||
| 2021-02-16 | Virgin Herbert EVP, Research & CSO | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2021-02-16 | Rice Steven J. Chief Administrative Officer | Grant or award | +20,000 | 20,000 | ||
| 2021-02-16 | Rice Steven J. Chief Administrative Officer | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2021-02-16 | SCANGOS GEORGE A President and CEO | Grant or award | +111,000 | 4,609,559 | ||
| 2021-02-16 | SCANGOS GEORGE A President and CEO | Grant or award · Stock Option (Right to Buy) | +222,000 | 222,000 | ||
| 2021-02-12 | Pang Phillip Chief Medical Officer | Option exercise | +10,000 | $0.86 | $9K | 67,277 |
| 2021-02-12 | Pang Phillip Chief Medical Officer | Option exercise · Employee Stock Option (Right to Buy) | −10,000 | 43,833 | ||
| 2021-02-09 | Virgin Herbert EVP, Research & CSO | Option exercise | +7,900 | $1.53 | $12K | 41,100 |
| 2021-02-09 | Virgin Herbert EVP, Research & CSO | Sale | −7,900 | $71.16 | $562K | 33,200 |
| 2021-02-09 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −7,900 | 372,255 | ||
| 2021-02-01 | Parrish Jay Chief Business Officer | Option exercise | +2,314 | $1.49 | $3K | 224,536 |
| 2021-02-01 | Parrish Jay Chief Business Officer | Option exercise | +4,630 | $1.58 | $7K | 229,166 |
| 2021-02-01 | Parrish Jay Chief Business Officer | Sale | −6,944 | $69.91 | $485K | 222,222 |
| 2021-02-01 | Parrish Jay Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −2,314 | 13,889 | ||
| 2021-02-01 | Parrish Jay Chief Business Officer | Option exercise · Stock Option (Right to Buy) | −4,630 | 41,666 | ||
| 2021-01-26 | Virgin Herbert EVP, Research & CSO | Option exercise | +31,300 | $1.53 | $48K | 64,500 |
| 2021-01-26 | Virgin Herbert EVP, Research & CSO | Sale | −31,300 | $48.17 | $1.5M | 33,200 |
| 2021-01-26 | Virgin Herbert EVP, Research & CSO | Option exercise · Stock Option (Right to Buy) | −31,300 | 380,155 | ||
| 2021-01-15 | Virgin Herbert EVP, Research & CSO | Option exercise | +10,530 | $1.53 | $16K | 43,730 |
Page 46 of 54 · 1,063 trades